In recent trading session, SELLAS Life Sciences Group Inc (NASDAQ:SLS) saw 1.13 million shares changing hands at last check today with its beta currently measuring 2.27. Company’s recent per share price level of $1.89 trading at $0.04 or 2.43% at last check today assigns it a market valuation of $189.08M. That most recent trading price of SLS’s stock is at a discount of -12.17% from its 52-week high price of $2.12 and is indicating a premium of 59.26% from its 52-week low price of $0.77. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.6 million shares which gives us an average trading volume of 2.23 million if we extend that period to 3-months.
For SELLAS Life Sciences Group Inc (SLS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.08 in the current quarter.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) trade information
Upright in the green today for gaining 2.43%, in the last five days SLS remained trading in the green while hitting it’s week-highest on Thursday, 06/26/25 when the stock touched $1.89 price level, adding 2.58% to its value on the day. SELLAS Life Sciences Group Inc’s shares saw a change of 56.61% in year-to-date performance and have moved 20.70% in past 5-day. SELLAS Life Sciences Group Inc (NASDAQ:SLS) showed a performance of -1.81% in past 30-days. Number of shares sold short was 18.9 million shares which calculate 6.6 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2.8 to the stock, which implies a rise of 32.5% to its recent value today. Analysts have been projecting 2.4 as a low price target for the stock while placing it at a high target of 3.2. It follows that stock’s current price would drop -26.98% in reaching the projected high whereas dropping to the targeted low would mean a loss of -26.98% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 45.94% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 36.67% while estimates for its earnings growth in next 5 years are of 33.56%.
SELLAS Life Sciences Group Inc (NASDAQ:SLS)’s Major holders
Insiders are in possession of 0.34% of company’s total shares while institution are holding 14.34 percent of that, with stock having share float percentage of 14.38%. Investors also watch the number of corporate investors in a company very closely, which is 14.34% institutions for SELLAS Life Sciences Group Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at SLS for having 1.79 million shares of worth $2.13 million. And as of 2024-06-30, it was holding 3.9862 of the company’s outstanding shares.
The second largest institutional holder is SUSQUEHANNA INTERNATIONAL GROUP, LLP, which was holding about 1.64 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.6594 of outstanding shares, having a total worth of $1.95 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 1.71 shares of worth $3.17 million or 1.72% of the total outstanding shares. The later fund manager was in possession of 1.03 shares on Mar 31, 2025 , making its stake of worth around $1.91 million in the company or a holder of 1.03% of company’s stock.
